Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07491172 · ClinicalTrials.gov registry record · Phase 1
A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias
A Phase 1 study, sponsored by CRISPR Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 90
- Enrollment target
NCT07491172: Recruiting Phase 1 study, sponsored by CRISPR Therapeutics.
NCT07491172 is a Phase 1 study that is actively recruiting participants, run by CRISPR Therapeutics. The registered enrollment target is 90 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07491172, a Phase 1 study, is actively recruiting participants, sponsored by CRISPR Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 90 participants
- Enrollment target
Study Summary
This is a single-arm, open-label, multicenter, ascending dose Phase 1 trial that will enroll participants 18 to 75 years of age with dyslipidemias that are refractory to available treatments.
Primary Outcome
Incidence of dose-limiting toxicities and frequency of adverse events
Interventions
- DRUG CTX310
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2024-06-21 |
| Est. Completion | 2028-06 |
| Phase | Phase 1 |
What NCT07491172 shows while recruiting
NCT07491172 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% higher).
The record links to 0 conditions, and to 1 intervention - of which CTX310 is the first listed.
NCT07491172 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07491172 about?
NCT07491172 is a clinical study titled "A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias". This is a single-arm, open-label, multicenter, ascending dose Phase 1 trial that will enroll participants 18 to 75 years of age with dyslipidemias that are refractory to available treatments.
What is the current status of trial NCT07491172?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2024-06-21. Estimated completion is 2028-06.
What interventions are being tested in trial NCT07491172?
The interventions under investigation include: CTX310 (DRUG).
Who is sponsoring clinical trial NCT07491172?
This trial is sponsored by CRISPR Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07491172's enrollment target sits among peer trials
90 628th of 2000 higher than 1,352 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI